In vivo FGFR inhibitor study
To date, the efficacy of FGFR-inhibitors against sarcomas has not been evaluated in vivo. We have xenograft models generated from some of the patient tumors with amplified FRS2, and also several cell lines, showing great sensitivity to FGFR inhibition. Since patients with liposarcoma are in need of improved treatment options, the therapeutic potential of FGFR inhibition should be more carefully assessed using liposarcoma xenograft models. In this study we plan to test the efficacy of the more potent FGFR-inhibitor, LY2874455 in vivo.
For this experiment we are planning to use 78 immune deficient mice. We are expecting minimum impact of the treatment on the animal welfare. The administration of the drug by gavage will be executed of very experienced technicians. Tumors will be implanted subcutaneous so the mice will not develop systemic disease or metastases.
For this experiment we are planning to use 78 immune deficient mice. We are expecting minimum impact of the treatment on the animal welfare. The administration of the drug by gavage will be executed of very experienced technicians. Tumors will be implanted subcutaneous so the mice will not develop systemic disease or metastases.